Loading...
XJPX
4594
Market cap29mUSD
Dec 05, Last price  
50.00JPY
1D
-1.96%
1Q
-35.06%
Jan 2017
-92.80%
IPO
-87.37%
Name

BrightPath Biotherapeutics Co Ltd

Chart & Performance

D1W1MN
XJPX:4594 chart
P/E
—
P/S
3,993.47
EPS
—
Div Yield, %
—
Shrs. gr., 5y
14.16%
Rev. gr., 5y
-36.87%
Revenues
1m
+1,473.61%
821,625,000822,556,000529,612,000354,410,000155,808,00011,300,0002,504,00015,408,0005,280,00072,0001,133,000
Net income
-1.15b
L-1.45%
-412,435,000-994,464,000-1,113,661,000-1,577,142,000-1,884,318,000-1,857,774,000-1,719,634,000-1,484,192,000-1,485,633,000-1,168,082,000-1,151,149,000
CFO
-1.25b
L+8.08%
-447,197,000-908,711,000-1,067,512,000-1,591,336,000-1,457,571,000-1,784,461,000-1,769,848,000-1,512,022,000-1,204,401,000-1,156,920,000-1,250,359,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

BrightPath Biotherapeutics Co., Ltd. develops cancer immunotherapy drugs. The company is developing GRN-1201 that is in Phase II clinical study for the treatment of non-small cell lung cancer, as well as in Phase I clinical study to treat melanoma. It also develops BP1101, a neoantigen vaccine; BP1209, a platform of personalized neoantigen cancer vaccines; and BP1401, an agonist for toll-like receptor 9. In addition, the company offers induced pluripotent stem cell derived regenerated NKT cell therapy for head and neck cancer; and BP2301, an autologous HER2 chimeric antigen receptor-T cell therapy for treating solid tumors sarcoma. Further, it is involved in discovering BP1200, an antibody targeting CD73; BP1210, an immune checkpoint inhibitory antibody; and other antibodies, such as BP1202, BP1206, and BP1211. The company was formerly known as GreenPeptide Co., Ltd. and changed its name to BrightPath Biotherapeutics Co., Ltd. in July 2017. BrightPath Biotherapeutics Co., Ltd. was founded in 2003 and is headquartered in Tokyo, Japan.
URL
https://www.brightpathbio.com/
IPO date
Oct 22, 2015
Employees
42
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT